Categories: News

HPAPI 2020 Conference to Discuss Containment Solutions and ADC Developments

SMi reports: The Highly Potent Active Pharmaceutical Ingredients conference will explore real-world examples of PBD payload synthesis, manufacture of oncology products and design of ADC containment systems.

London, United Kingdom, February 12, 2020 –(PR.com)– On the 11th – 12th May 2020, industry professionals will convene in London to discuss the challenges of the HPAPI industry at the Highly Potent Active Pharmaceutical Ingredients conference.

The global market for Highly Potent Active Pharmaceutical Ingredients has experienced an increased growth, resulting from its major use in oncology for cancer treatment – more often in the form of antibody drug conjugates (ADC).

With this in mind, one of the underlying subjects of the conference will be on containment solutions and ADC developments, where real-world examples of PBD payload synthesis, manufacture of oncology products and design of ADC containment systems will be discussed in fine detail. The conference will feature three briefings dedicated to these topics from leading industry professionals:
1) CMC Strategies for the Timely Launch Preparation of Antibody-Drug-Conjugates as High Potent APIs
· The manufacture of highly potent ADCs – challenges and solutions
· Deciding when to outsource and when to keep in-house
· Bayer’s ADC production concept
· Best practices for CMO selection and outsourcing ADC development and manufacture
· The journey from development to launch – understanding the needs, solutions, risks and mitigations
Presented by Ulrich Ruemenapp, Head of Launch preparation and Coordination, Bayer Ag

2) Engineering in Support of ADC Containment – a Case Study
· Innovative solutions to dealing with increasing toxicity of ADCs
· Designing ADC containment systems
· The containment of ADCs – a case study from AZ
Presented by Peter Marshall, Associate Engineering Director, AstraZeneca

3) Manufacturing of Oncological Products: a Perspective by a CDMo
· New Product Introduction
· Cross Contamination Risk Assessment & Environmental Risk Assessment
· Case Study: ADC Manufacturing

Presented by Fabio Zenobi, EHS Director, BSP Pharmaceuticals

Interested parties can view the full agenda and register for the event online.

Highly Potent Active Pharmaceutical Ingredients
Main conference: 11th-12th May 2020
Post-conference workshop day: 13th May 2020
London, UK
Sponsored by: BSP Pharmaceuticals

Let’s block ads! (Why?)

Miscw.com

Recent Posts

St. George’s University Emphasizes Pathology’s Critical Role in Advancing South Korea’s Healthcare Systems on World Pathology Day

SEOUL, SOUTH KOREA - Media OutReach Newswire - 6 November 2024 - On World Pathology…

40 mins ago

Traders’ attitude to charity: global broker Octa’s research

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 31 October 2024 - E-brokerage is a…

15 hours ago

Dusit Foods partners with Japanese food industry giant Green House to drive global expansion of Epicure Catering

Strategic alliance poised to create new growth avenues in Thailand, Japan, and beyond. BANGKOK, THAILAND…

17 hours ago

Leonteq Launches Shari’a-Compliant Offering on LYNQS

Leonteq announced today that it has enabled its Shari’a-compliant structured product offering on its digital…

18 hours ago

OZONO Launches in Australia with Innovative Eco-Friendly Cleaning Technology

Revolutionizing Home and Commercial Cleaning with Aqueous Ozone Solutions that are hypoallergenic & eco-friendly QUEENSLAND,…

19 hours ago

Use More to Get More with Citi This Travel Season

Enjoy up to 10% rebate and chance to win business class round trip to Tokyo…

19 hours ago